Its overexpression has been identified as a biomarker for HPD, with studies showing that MDM2 suppresses anti-tumor immunity by reducing T cell activation and promoting an immunosuppressive environment (Adashek et al., 2020). The gene discussed is MDM2; the disease is neoplasm.